Loading...

Moderna, Inc.

0QF.FXETRA
Healthcare
Biotechnology
23.94
-4.34(-15.36%)

Moderna, Inc. (0QF.F) Stock Competitors & Peer Comparison

See (0QF.F) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
0QF.F€23.94-15.36%10.2B-3.50-€7.56N/A
NOV.DE€41.90-5.61%193.9B13.16€3.14+3.56%
VX1.DE€402.20-2.18%104.9B-124.10-€3.29N/A
DUL.DE€227.20+0.00%27.3B-31.91-€7.12N/A
22UA.F€91.00-5.65%23.1B-30.08-€3.19N/A
BM8.DE€61.96-1.71%11.8B88.51€0.70N/A
EX9.DE€32.28+1.22%9.2B35.47€0.91N/A
MOR.DE€67.25-0.66%2.5B-12.16-€5.53N/A
BBZA.DE€34.30-0.87%1.9B-4.28-€8.31+5.24%
BIO3.DE€28.40-3.40%1.4B-45.08-€0.63+0.14%
Showing 1 to 10 of 34 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

0QF.F vs NOV.DE Comparison August 2025

0QF.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 0QF.F stands at 10.2B. In comparison, NOV.DE has a market cap of 193.9B. Regarding current trading prices, 0QF.F is priced at €23.94, while NOV.DE trades at €41.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

0QF.F currently has a P/E ratio of -3.50, whereas NOV.DE's P/E ratio is 13.16. In terms of profitability, 0QF.F's ROE is -0.30%, compared to NOV.DE's ROE of +0.81%. Regarding short-term risk, 0QF.F is more volatile compared to NOV.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 0QF.F.Check NOV.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;